Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025)
Inhibrx Biosciences (INBX) reported EPS (Weighted Average and Diluted) of -$2.11 for Q4 2025, up 52.8% year-over-year from -$1.38 in Q4 2024, and up 7.46% quarter-over-quarter from -$2.28 in Q3 2025.
Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of EPS (Weighted Average and Diluted) data on file, last reported at -$2.11 in Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$2.11, up 52.8% year-over-year; the trailing twelve-month figure through Dec 2025 was -$9.04 (down 108.04% YoY), and the FY2025 annual result was -$9.04, down 108.03% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$2.11 in Q4 2025 per INBX's latest filing, from -$2.28 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $125.48 in Q2 2024 and troughed at -$7.29 in Q4 2023.
- A 3-year average of $7.94 and a median of -$2.84 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 3011.37% in 2024, then sank 101.47% in 2025.
- A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$7.29 in 2023, then soared by 38.68% to -$4.47 in 2024, then soared by 52.8% to -$2.11 in 2025.
- Business Quant data shows INBX's EPS (Weighted Average and Diluted) at -$2.11 in Q4 2025, -$2.28 in Q3 2025, and -$1.85 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | -2.11 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.11 |
| Sep 30, 2025 | -2.28 |
| Jun 30, 2025 | -1.85 |
| Mar 31, 2025 | -2.80 |
| Dec 31, 2024 | -4.47 |
| Sep 30, 2024 | -2.84 |
| Jun 30, 2024 | 125.48 |
| Mar 31, 2024 | -5.77 |
| Dec 31, 2023 | -7.29 |
| Sep 30, 2023 | -4.39 |
| Jun 30, 2023 | -4.31 |